Press Coverage

Research Shows Promising Long-Term Outcomes For New Vascular Graft Treatment

Somahlution recently released results of a study on long-term outcomes in procedures using their vascular graft treatment product, Duragraft. The company, based in Jupiter, Florida, is celebrating the highly encouraging results [...]

Novel treatment to prevent vein graft failure confers improved outcomes after CABG

Researchers conducted a retrospective, nonrandomized real-world study of 2,436 patients who had CABG with at least one saphenous vein graft. In the cohort, 1,036 were treated with the vascular graft treatment designed to protect [...]

DuraGraft Vascular Graft Evaluated to Prevent Vein Graft Failure After CABG

Dr. Haime discusses an abstract about Somahlution DuraGraft during a rapid response session at the 2016 annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS; 1–5 October, Barcelona, Spain) [...]

Intraoperative Vascular Graft Treatment Shown to Reduce Risk of Graft Failure

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

EACTS 2016: DuraGraft vascular graft treatment improves long-term outcomes after CABG

Somahlution announced the presentation of new data showing the its DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery. Results were presented today [...]

Somahlution Announces Study Results Showing DuraGraft Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]

Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft

Somahlution's DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery [...]

Somahlution Announces Study Results Showing DuraGraft Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery

Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]